US Biosimilars ‘Bumpy’ For Teva As It Prepares For Alvotech Inspection

CEO Hints At More Deals On The Horizon Despite A Degree Of Market Uncertainty

 
• By Dave Wallace

Offering the latest details on Teva’s biosimilars strategy, CEO Richard Francis spoke about how the firm is looking to bring Alvotech’s FDA filings to the finish line as well as hinting at future biosimilars partnership deals. At the same time, he acknowledged a “bumpy” US market with a degree of uncertainty that has led the firm to allocate capital accordingly.

Road sign warning of bumps ahead
Teva’s CEO sees the US market as “bumpy” • Source: Shutterstock

Teva’s management has expressed confidence in helping to resolve manufacturing issues at its US biosimilars partner Alvotech and has also hinted at new biosimilars deals on the horizon in the near future. However, at the same time the firm’s CEO acknowledged that the “bumpy” US market was still carrying a degree of uncertainty that is leading the firm to allocate capital accordingly.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business